|
186 Companies |
|
244 Products |
|
244 Products |
|
91 Mechanisms of Action |
|
17 Trials |
|
2576 News |
|
| «12...7891011121314151617...5253» |
- cyclophosphamide / Generic mfg.
Trial termination: Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) (clinicaltrials.gov) - Jun 17, 2016
P2, N=88, Terminated, Sponsor: Stanford University
Completed --> Terminated
- zoledronic acid / Generic mfg.
Trial initiation date, Trial primary completion date, Head-to-Head: Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 14, 2016
P4, N=280, Not yet recruiting, Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Completed --> Terminated Initiation date: Oct 2015 --> Jun 2016 | Trial primary completion date: Apr 2017 --> Apr 2018
- Enrollment open, Trial primary completion date: PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism (clinicaltrials.gov) - Jun 13, 2016
P=N/A, N=100, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Initiation date: Oct 2015 --> Jun 2016 | Trial primary completion date: Apr 2017 --> Apr 2018 Withdrawn --> Recruiting | Trial primary completion date: Sep 2014 --> Sep 2017
- Trial primary completion date: Randomized Double Cord Blood Transplant Study (clinicaltrials.gov) - Jun 11, 2016
P2, N=110, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Withdrawn --> Recruiting | Trial primary completion date: Sep 2014 --> Sep 2017 Trial primary completion date: Jun 2017 --> Jun 2018
- clofarabine / Generic mfg.
Trial termination: Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients (clinicaltrials.gov) - Jun 11, 2016
P1, N=4, Terminated, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Jun 2017 --> Jun 2018 Completed --> Terminated; Drug provider withdrew support
- | PLX51107 / Daiichi Sankyo
Metastases: A Study of PLX51107 in Advanced Malignancies (clinicaltrials.gov) - Jun 9, 2016
P1b, N=60, Recruiting, Sponsor: Plexxikon
Completed --> Terminated; Drug provider withdrew support Phase classification: P1 --> P1b
- azacitidine / Generic mfg.
Trial primary completion date, Combination therapy: A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients (clinicaltrials.gov) - Jun 1, 2016
P1, N=36, Recruiting, Sponsor: Groupe Francophone des Myelodysplasies
Phase classification: P1 --> P1b Trial primary completion date: Apr 2016 --> Sep 2016
- |||| Besremi (ropeginterferon alfa-2b) / PharmaEssentia, AOP Orphan Pharma
Trial primary completion date: PROUD-PV: Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (clinicaltrials.gov) - Jun 1, 2016
P3, N=256, Active, not recruiting, Sponsor: AOP Orphan Pharmaceuticals AG
Trial primary completion date: Apr 2016 --> Sep 2016 Trial primary completion date: Mar 2016 --> Jul 2016
- | Promacta (eltrombopag) / Novartis
Enrollment closed, Enrollment change: Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia (clinicaltrials.gov) - May 31, 2016
P2, N=13, Active, not recruiting, Sponsor: University of Utah
Trial primary completion date: Mar 2016 --> Jul 2016 Recruiting --> Active, not recruiting | N=30 --> 13
- | zoledronic acid / Generic mfg.
New P2 trial, Combination therapy: Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors (clinicaltrials.gov) - May 27, 2016
P2, N=60, Recruiting, Sponsor: Severance Hospital
- ||||||| Anathromb (anagrelide CR) / AOP Orphan Pharma
Trial completion, Enrollment change, Trial primary completion date: ARETA: Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia (clinicaltrials.gov) - May 27, 2016
P3, N=146, Completed, Sponsor: AOP Orphan Pharmaceuticals AG
Recruiting --> Active, not recruiting | N=30 --> 13 Active, not recruiting --> Completed | N=280 --> 146 | Trial primary completion date: Mar 2016 --> Jan 2015
- Mobista (CDX-301) / Celldex
Trial termination, IO biomarker: A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs (clinicaltrials.gov) - May 24, 2016
P2, N=36, Terminated, Sponsor: Celldex Therapeutics
Active, not recruiting --> Completed | N=280 --> 146 | Trial primary completion date: Mar 2016 --> Jan 2015 Active, not recruiting --> Terminated
- Enrollment change, Trial termination, Trial primary completion date, Surgery: Cryosurgery and Radiation Therapy in Treating Patients With Painful Bone Metastases (clinicaltrials.gov) - May 24, 2016
P=N/A, N=1, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Terminated N=15 --> 1 | Recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Dec 2014; Slow Accruals
- Enrollment change, Trial termination: AMC-HEMREG-CML: Chronic Myelod Leukemia Registry at Asan Medical Center (clinicaltrials.gov) - May 24, 2016
P=N/A, N=100, Terminated, Sponsor: Asan Medical Center
N=1050 --> 100 | Recruiting --> Terminated; The PI resigned the institute. The rest investigators at the institute decided to terminate the study.
- ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Clinical: Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis (clinicaltrials.gov) - May 23, 2016
P2, N=6, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
The rest investigators at the institute decided to terminate the study. Recruiting --> Active, not recruiting | N=47 --> 6 | Trial primary completion date: Jan 2015 --> Jan 2017
- dilanubicel (DVX101) / Deverra Therapeutics
Trial completion: Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies (clinicaltrials.gov) - May 23, 2016
P2, N=15, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting | N=47 --> 6 | Trial primary completion date: Jan 2015 --> Jan 2017 Active, not recruiting --> Completed
- ||| Biomarker, Trial completion, Trial primary completion date: Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=250, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- Trial primary completion date: Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - May 19, 2016
P1/2, N=52, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Trial primary completion date: Jun 2016 --> Dec 2016
- ||| Biomarker, Trial completion, Trial primary completion date: Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder (clinicaltrials.gov) - May 19, 2016
P=N/A, N=60, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Jun 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- | Trial completion, Trial initiation date, Trial primary completion date: Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=20, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Completed | Initiation date: Oct 2009 --> May 2009 | Trial primary completion date: Jan 2100 --> May 2016
- | volasertib (NBL-001) / Oncoheroes, Notable Labs
Trial suspension, Combination therapy: Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML (clinicaltrials.gov) - May 18, 2016
P1, N=88, Suspended, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | Initiation date: Oct 2009 --> May 2009 | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Suspended
- Trial completion, Enrollment change, Trial primary completion date: Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. (clinicaltrials.gov) - May 18, 2016
P=N/A, N=50, Completed, Sponsor: Beth Israel Medical Center
Recruiting --> Suspended Recruiting --> Completed | N=40 --> 50 | Trial primary completion date: Dec 2016 --> Oct 2015
- |||| Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
Trial primary completion date: Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) (clinicaltrials.gov) - May 16, 2016
P3, N=260, Active, not recruiting, Sponsor: Neovii Biotech
Recruiting --> Completed | N=40 --> 50 | Trial primary completion date: Dec 2016 --> Oct 2015 Trial primary completion date: Feb 2016 --> Sep 2016
- || Promacta (eltrombopag) / Novartis
New P2/3 trial, Combination therapy: Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA) (clinicaltrials.gov) - May 16, 2016
P2/3, N=116, Recruiting, Sponsor: B. H
- ||| Trial completion: Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF (clinicaltrials.gov) - May 14, 2016
P=N/A, N=494, Completed, Sponsor: Medtronic Spinal and Biologics
Trial primary completion date: Feb 2016 --> Sep 2016 Active, not recruiting --> Completed
- pioglitazone / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia (clinicaltrials.gov) - May 13, 2016
P2, N=26, Recruiting, Sponsor: Emory University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> May 2016 | Trial primary completion date: Sep 2021 --> May 2021
- imatinib / Generic mfg.
Trial primary completion date: Late Chronic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - May 11, 2016
P2, N=47, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> May 2016 | Trial primary completion date: Sep 2021 --> May 2021 Trial primary completion date: Sep 2013 --> Dec 2006
- |||| Leukine (sargramostim) / Partner Therap, ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial primary completion date, Combination therapy: High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) (clinicaltrials.gov) - May 11, 2016
P3, N=94, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2013 --> Dec 2006 Trial primary completion date: Aug 2015 --> Apr 2007
- decitabine / Generic mfg.
Trial initiation date, Trial primary completion date: Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - May 9, 2016
P1, N=12, Completed, Sponsor: Eisai Inc.
Trial primary completion date: Aug 2015 --> Apr 2007 Initiation date: Sep 2009 --> Dec 2009 | Trial primary completion date: Dec 2010 --> Sep 2011
- New P2 trial: StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies (clinicaltrials.gov) - May 9, 2016
P2, N=30, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
- ||| zotiraciclib (TG02) / Cothera Biosci
Metastases: Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies (clinicaltrials.gov) - May 6, 2016
P1, N=120, Completed, Sponsor: Tragara Pharmaceuticals, Inc.
Initiation date: Sep 2009 --> Dec 2009 | Trial primary completion date: Dec 2010 --> Sep 2011 Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Mar 2016
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies (clinicaltrials.gov) - May 6, 2016
P2, N=23, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Mar 2016 Active, not recruiting --> Completed
- Campath (alemtuzumab) / Sanofi, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion, Trial primary completion date: Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia (clinicaltrials.gov) - May 6, 2016
P2, N=136, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> May 2016
- Trial completion, Enrollment change, Trial primary completion date: Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant (clinicaltrials.gov) - May 6, 2016
P=N/A, N=48, Completed, Sponsor: Duke University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> May 2016 Recruiting --> Completed | N=500 --> 48 | Trial primary completion date: Jul 2020 --> Apr 2016
- Coversin SC (nomacopan SC) / Akari Therap
Enrollment open, Trial initiation date, Trial primary completion date: Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) (clinicaltrials.gov) - May 5, 2016
P2, N=6, Recruiting, Sponsor: AKARI Therapeutics
Recruiting --> Completed | N=500 --> 48 | Trial primary completion date: Jul 2020 --> Apr 2016 Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Jan 2016 | Trial primary completion date: Apr 2016 --> Dec 2016
- ||| volasertib (NBL-001) / Oncoheroes, Notable Labs
Enrollment open, Combination therapy, Monotherapy: Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - May 4, 2016
P1, N=85, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Jan 2016 | Trial primary completion date: Apr 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- Campath (alemtuzumab) / Sanofi, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia (clinicaltrials.gov) - May 3, 2016
P2, N=136, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2018 --> Dec 2016
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Phase classification: Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis (clinicaltrials.gov) - May 3, 2016
P2, N=66, Active, not recruiting, Sponsor: John Mascarenhas
Trial primary completion date: Jul 2018 --> Dec 2016 Phase classification: P=N/A --> P2
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment open, Enrollment change, Post-transplantation: Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT (clinicaltrials.gov) - May 3, 2016
P2, N=60, Recruiting, Sponsor: St. Petersburg State Pavlov Medical University
Phase classification: P=N/A --> P2 Active, not recruiting --> Recruiting | N=200 --> 60
- Clinical: Dual Energy Computed Tomography (CT) in Finding Bone Metastases in Patients With Cancer (clinicaltrials.gov) - May 2, 2016
P=N/A, N=45, Recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Recruiting | N=200 --> 60 Trial primary completion date: Apr 2016 --> Nov 2016
- Trial termination: Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation (clinicaltrials.gov) - May 2, 2016
P2, N=12, Terminated, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Apr 2016 --> Nov 2016 Active, not recruiting --> Terminated; Investigator's decision.
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial primary completion date: Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 29, 2016
P=N/A, N=90, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Terminated; Investigator's decision. Trial primary completion date: Jun 2016 --> Dec 2016
- Enrollment closed: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 27, 2016
P1, N=30, Active, not recruiting, Sponsor: Stanford University
Trial primary completion date: Jun 2016 --> Dec 2016 Suspended --> Active, not recruiting
- Rydapt (midostaurin) / Novartis
Enrollment closed, Combination therapy: Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 27, 2016
P2, N=36, Active, not recruiting, Sponsor: Bruno C. Medeiros
Suspended --> Active, not recruiting Suspended --> Active, not recruiting
- ||| dasatinib / Generic mfg.
Trial completion, Trial primary completion date: Korean Post-marketing Surveillance for Sprycel (clinicaltrials.gov) - Apr 27, 2016
P=N/A, N=670, Completed, Sponsor: Bristol-Myers Squibb
Suspended --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: May 2016 --> Aug 2015
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment closed: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 27, 2016
P1, N=19, Active, not recruiting, Sponsor: Bruno C. Medeiros
Recruiting --> Completed | Trial primary completion date: May 2016 --> Aug 2015 Suspended --> Active, not recruiting
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Enrollment closed: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 27, 2016
P2, N=33, Active, not recruiting, Sponsor: Bruno C. Medeiros
Suspended --> Active, not recruiting Suspended --> Active, not recruiting
- ||| Mycamine (micafungin) / Astellas, Noxafil (posaconazole) / Merck (MSD)
Enrollment closed, Trial primary completion date: Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 26, 2016
P4, N=117, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Sep 2017
- IRX5183 / Io Therap
New P1/2 trial: Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 25, 2016
P1/2, N=40, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- Trial completion: Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Apr 22, 2016
P1/2, N=30, Completed, Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Completed